• TREATMENT

    Daraxonrasib receives first FDA approval for pancreatic cancer

    The oral RAS(ON) inhibitor daraxonrasib was approved in the U.S. on August 26, 2026, for metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy; the drug is being developed for solid tumors including CRC and lung cancer. (Drugs)